gene

MET

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MET: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

662Connections

30Hypotheses

30Analyses

50Outgoing

50Incoming

Summary

Page for MET - MET Proto-Oncogene, Receptor Tyrosine Kinase

View on Wiki →

🧬 Gene Info

Gene Symbol	MET
Full Name	MET Proto-Oncogene, Receptor Tyrosine Kinase
Aliases	Page for MET, c-Met
Chromosome	7q31.2
Protein Type	Receptor
Function	is a receptor tyrosine kinase (RTK) that plays crucial roles in embryonic development, tissue regeneration, and adult tissue homeostasis.
Molecular Weight	~140 kDa (precursor), ~170 kDa (mature)
Amino Acids	1390 aa
Exons	21
Pathways	Key Effectors
UniProt ID	P08581
NCBI Gene ID	4233
Ensembl ID	ENSG00000105976
OMIM	164860
GeneCards	MET
Human Protein Atlas	MET
Associated Diseases	AD, ALI, AMI, Aging, Als, Alzheimer
Known Drugs/Compounds	PLB-1001, resveratrol, metformin
Interactions	BRAF, EGFR, C1Q, MIRO1, MCL1, VEGFA
KG Connections	662 knowledge graph edges
Databases	GeneCards HPA STRING

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    MET["MET"] -->|"associated"| glioblastoma["glioblastoma"]
    MET["MET"] -->|"activates"| glioma_progression["glioma progression"]
    MET["MET"] -->|"biomarker for"| secondary_glioblastoma["secondary glioblastoma"]
    MET["MET"] -->|"therapeutic target"| Cancer["Cancer"]
    MET["MET"] -->|"expressed in"| Carcinoma["Carcinoma"]
    MET["MET"] -->|"therapeutic target"| Ms["Ms"]
    PTPRZ1["PTPRZ1"] -->|"interacts"| MET["MET"]
    PLB_1001["PLB-1001"] -.->|"inhibits"| MET["MET"]
    IDH1["IDH1"] -->|"therapeutic target"| MET["MET"]
    VEGFA["VEGFA"] -->|"therapeutic target"| MET["MET"]
    style MET fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (415)

Target	Relation	Type	Str
Cancer	therapeutic_target	disease	1.00
Als	therapeutic_target	disease	1.00
acquired resistance	promotes	phenotype	0.90
MET Signaling	regulates	pathway	0.85
Als	associated_with	disease	0.85
Inflammation	associated_with	disease	0.85
Inflammation	therapeutic_target	disease	0.85
Alzheimer's Disease	downregulates	disease	0.85
GSK3B	regulates	protein	0.80
Depression	associated_with	disease	0.75
Alzheimer	therapeutic_target	disease	0.75
Parkinson	therapeutic_target	disease	0.75
Diabetes	therapeutic_target	disease	0.75
Glioblastoma	therapeutic_target	disease	0.75
Cancer	regulates	disease	0.75
Cancer	activates	disease	0.75
Carcinoma	activates	disease	0.75
Tumor	inhibits	disease	0.75
Tumor	regulates	disease	0.75
Schizophrenia	associated_with	disease	0.75
Als	activates	disease	0.75
Neurodegeneration	therapeutic_target	disease	0.75
Neuroinflammation	therapeutic_target	disease	0.75
Cancer	associated_with	disease	0.75
Stroke	therapeutic_target	disease	0.75
Tumor	activates	disease	0.75
Fibrosis	activates	disease	0.75
Infection	activates	disease	0.75
endothelial cells	expressed_in	cell_type	0.75
glioma progression	activates	process	0.70
secondary glioblastoma	biomarker_for	disease	0.70
Oxidative Stress	associated_with	pathway	0.70
glioblastoma	associated_with	disease	0.70
Mtor	therapeutic_target	pathway	0.70
Mapk	regulates	pathway	0.70
Autophagy	activates	pathway	0.70
Mapk	activates	pathway	0.70
Apoptosis	activates	pathway	0.70
Stem Cell	therapeutic_target	pathway	0.70
Oxidative Stress	therapeutic_target	pathway	0.70
Wnt signaling	participates_in	pathway	0.70
Ptsd	associated_with	disease	0.65
Carcinoma	expressed_in	disease	0.65
Ms	therapeutic_target	disease	0.65
Als	expressed_in	disease	0.65
Ms	associated_with	disease	0.65
Anxiety	associated_with	disease	0.65
Ms	activates	disease	0.65
Depression	activates	disease	0.65
Amyotrophic Lateral Sclerosis	therapeutic_target	disease	0.65

Incoming (247)

Source	Relation	Type	Str
PI3K	activates	gene	0.90
CANCER	therapeutic_target	gene	0.90
Circular RNA	associated_with	biological_process	0.80
AKT	activates	gene	0.80
EGFR	inhibits	gene	0.80
PLB-1001	inhibits	drug	0.70
PI3K	therapeutic_target	gene	0.70
AKT	therapeutic_target	gene	0.70
SUST	associated_with	gene	0.70
PTPRZ1	interacts_with	gene	0.70
CANCER	regulates	gene	0.70
CANCER	activates	gene	0.70
OXIDATIVE STRESS	associated_with	gene	0.70
DEPRESSION	associated_with	gene	0.70
NEURODEGENERATION	therapeutic_target	gene	0.70
INFLAMMATION	associated_with	gene	0.70
CANCER	associated_with	gene	0.70
STROKE	therapeutic_target	gene	0.70
AUTOPHAGY	activates	gene	0.70
OXIDATIVE STRESS	therapeutic_target	gene	0.70
IDH1	therapeutic_target	gene	0.60
VEGFA	therapeutic_target	gene	0.60
MDM4	therapeutic_target	gene	0.60
APOB	inhibits	gene	0.60
SF3B1	therapeutic_target	gene	0.60
WIF1	associated_with	gene	0.60
NPTX2	inhibits	gene	0.60
SOD2	therapeutic_target	gene	0.60
CDC42	therapeutic_target	gene	0.60
CYCS	therapeutic_target	gene	0.60
GFAP	therapeutic_target	gene	0.60
RAC1	therapeutic_target	gene	0.60
GADD45A	activates	gene	0.60
GADD45B	activates	gene	0.60
GADD45G	activates	gene	0.60
TERT	therapeutic_target	gene	0.60
SMARCA4	therapeutic_target	gene	0.60
JUN	therapeutic_target	gene	0.60
EEF1A1	therapeutic_target	gene	0.60
MCL1	therapeutic_target	gene	0.60
C9ORF72	therapeutic_target	gene	0.60
MTOR	therapeutic_target	gene	0.60
EGFR	therapeutic_target	gene	0.60
IGF1	therapeutic_target	gene	0.60
MMP9	therapeutic_target	gene	0.60
PI3K	regulates	gene	0.60
AKT1	therapeutic_target	gene	0.60
HIF1A	therapeutic_target	gene	0.60
HSP90AA1	therapeutic_target	gene	0.60
CASP3	therapeutic_target	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
SASP-Driven Microglial Metabolic Reprogramming in Synaptic P	0.638	neurodegeneration	Senolytic therapy for age-related neurod
p38α Inhibitor and PRMT1 Activator Combination to Restore Ph	0.615	neurodegeneration	What is the therapeutic window between i
Digital Twin-Guided Metabolic Reprogramming	0.605	neurodegeneration	Digital biomarkers and AI-driven early d
HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43	0.598	neurodegeneration	What is the therapeutic window between i
Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Met	0.593	neuroinflammation	What molecular mechanisms determine whet

Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove	0.592	neurodegeneration	Epigenetic reprogramming in aging neuron
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming	0.589	neurodegeneration	Gene expression changes in aging mouse b
TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging	0.587	neurodegeneration	Gene expression changes in aging mouse b
TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulati	0.563	neuroimmunology	What is the temporal sequence of TREM2 s
Adenosine-Astrocyte Metabolic Reset	0.557	neurodegeneration	Sleep disruption as cause and consequenc
Temporal Metabolic Window Therapy	0.506	neurodegeneration	How do astrocyte-neuron metabolic intera
Disease-Associated Microglia Metabolic Reprogramming	0.502	neurodegeneration	Cell type vulnerability in Alzheimers Di
APOE4-Specific Microglial Metabolic Rescue	0.498	-	Neuroinflammation and microglial priming
Lactate/Pyruvate Ratio Dynamics in CSF as a Neuroinflammatio	0.486	translational neuroscience	Which metabolic biomarkers can distingui
Metabolic Switch Targeting for A1→A2 Repolarization	0.481	neurodegeneration	Astrocyte reactivity subtypes in neurode
Complement C1q Mimetic Decoy Therapy	0.479	neurodegeneration	Synaptic pruning by microglia in early A
Astrocyte APOE4-Specific Lipid Metabolism Correction	0.479	neurodegeneration	Cell type vulnerability in Alzheimers Di
Astrocyte Metabolic Memory Reprogramming	0.478	neurodegeneration	How do astrocyte-neuron metabolic intera
Metabolic Circuit Breaker via Lipid Droplet Modulation	0.476	neurodegeneration	Microglia-astrocyte crosstalk amplificat
Cell-Type Specific Metabolic Reprogramming	0.471	neurodegeneration	Cell type vulnerability in Alzheimers Di
TET2-Mediated Demethylation Rejuvenation Therapy	0.469	neurodegeneration	Epigenetic clocks and biological aging i
Arginine Methylation Enhancement Therapy	0.463	neurodegeneration	TDP-43 phase separation therapeutics for
Circadian-Metabolic Microglial Reprogramming	0.462	-	Neuroinflammation and microglial priming
Interfacial Lipid Mimetics to Disrupt Domain Interaction	0.459	neurodegeneration	APOE4 structural biology and therapeutic
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli	0.455	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
Restoring Neuroprotective Tryptophan Metabolism via Targeted	0.452	neurodegeneration	What are the mechanisms by which gut mic
Astrocyte Metabolic Reprogramming via APOE4 Correction	0.451	neurodegeneration	Cell type vulnerability in Alzheimer's D
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci	0.451	neurodegeneration	CRISPR-based therapeutic approaches for
TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR	0.451	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro
Microbial Metabolite-Mediated α-Synuclein Disaggregation	0.448	neurodegeneration	What are the mechanisms by which gut mic

Mentioning Analyses (30)

Scientific analyses that reference this entity

Are age-related static epigenetic patterns pathogenic or protective compensatory

epigenetics | 2026-04-15 | 0 hypotheses

What molecular mechanisms link elevated sphingomyelin synthase activity to incre

neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.542

Why does Metformin fail to delay CJD progression despite improving anti-aging ha

neurodegeneration | 2026-04-14 | 0 hypotheses

What specific molecular mechanisms link APOE4 to cholesterol dysregulation in ol

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.505

What is the molecular mechanism by which oligodendroglial MCT1 disruption causes

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.614

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Glucose Metabolic Reprogramming in Microglia: Implications for Neurodegenerative [PMID:39987285]	Fang M, Zhou Y, He K, Lu Y, Tao F, Huang	Mol Neurobiol	2025	1
Metformin restores mitochondrial bioenergetics and redox homeostasis through mod [PMID:40327990]	Brondani M, Ribeiro RT, Pinheiro CV, Hof	Biomed Pharmacother	2025	1
System biology-based assessment of the molecular mechanism of epigallocatechin g [PMID:40664965]	Fanai HL, Chand J, Ahmad SF, Attia SM, E	Sci Rep	2025	1
Minutes of PPAR-γ agonism and neuroprotection. [PMID:32758586]	Prashantha Kumar BR, Kumar AP, Jose JA,	Neurochem Int	2020	1
A lineage-resolved molecular atlas of C. elegans embryogenesis at single-cell re [PMID:31488706]	Packer JS, Zhu Q, Huynh C, Sivaramakrish	Science	2019	1
Metabolic asymmetry and the global diversity of marine predators. [PMID:30679341]	Grady JM, Maitner BS, Winter AS, Kaschne	Science	2019	1
A Never-Ending Story of Per- and Polyfluoroalkyl Substances (PFASs)? [PMID:28224793]	Wang Z, DeWitt JC, Higgins CP, Cousins I	Environ Sci Technol	2017	1
Gene Expression by Mouse Inner Ear Hair Cells during Development. [PMID:25904789]	Scheffer DI, Shen J, Corey DP, Chen ZY	J Neurosci	2015	1
The pharmacogenetics of type 2 diabetes: a systematic review. [PMID:24558078]	Nisa M Maruthur, Matthew O Gribble, Wend	Diabetes care	2014	1
Chapter 6: Structural variation and medical genomics. [PMID:23300412]	Raphael BJ	PLoS Comput Biol	2012	1
Caffeine and adenosine. [PMID:20164566]	Ribeiro JA, Sebastião AM	J Alzheimers Dis	2010	1
De novo purine synthesis reprograms the macrophage inflammatory response and the [PMID:41756441]	Haskó G, Liu L, Németh ZH, Wagener G, Ak	Research square	2026	0
Parthenolide inhibits methamphetamine-induced depressive-like behavior by target [PMID:41795299]	Hui R, Feng T, Hou C, Xu J, Zhang R, Ji	Phytomedicine : international	2026	0
Adenosine 2A receptor-dependent activation of AMPK represses TH17 cell pathogeni [PMID:40986641]	Papadopoulou G, Valakos D, Polydouri I,	Science signaling	2025	0
Surface d-Band Modulation via Biodirected Mineralization Enables Nanoenzymes to [PMID:41073355]	Li X, Zhao Q, Feng X, Cui P, Yu J, Liang	ACS nano	2025	0
Endothelial adenosine receptor 2A loss alleviates diabetic vascular calcificatio [PMID:41067595]	Zhou Y, Zhao D, Ma Q, Xu J, Cai Y, Yang	Pharmacological research	2025	0
Targeting adenosine 2A receptor signaling suppresses vascular calcification by r [PMID:41201506]	Zhou Y, Zhao D, Ma Q, Lee S, Roh K, Cai	Pharmacological research	2025	0
Polystyrene microplastics induced spermatogenesis disorder via disrupting mitoch [PMID:39577614]	["Jin H", "Xue B", "Chen X", "Ma T", "Ma	Environmental pollution (Barki	2025	0
p75NTR Modulation by LM11A-31 Counteracts Oxidative Stress and Cholesterol Dysme [PMID:41045381]	["Pensabene D", "Martella N", "Scavo G",	Neurochemical research	2025	0
PSMD4 Alleviates Aβ₁₋₄₂-Induced Mitochondrial Dysfunction and Oxidative Stress v [PMID:41269417]	["Yuan M", "Han X", "Luo C", "Pan H", "Z	Molecular neurobiology	2025	0

MET

Understanding Entity Pages

Summary

Wiki Pages (21)

MET - MET Proto-Oncogene, Receptor Tyrosine Kinase

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

CBS/PSP Supplements Guide

Device Therapies Comparison for CBS/PSP

Alpha-Synuclein Pathology

PD Combination Therapy Matrix

nimodipine-als

Alzheimer's Disease

Growth Factor Therapies

rasagiline

omega-3-fatty-acids-neurodegeneration

Clinical Trials Dashboard

Ferroptosis in Alzheimer's Disease

metal-ion-synuclein-mitochondria-axis-parkinsons

Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)

RNA Therapeutics for Neurodegeneration Investment Landscape

Ambroxol for Neurodegeneration (GCase Chaperone Strategy)

Idorsia Pharmaceuticals Ltd.

Bepranemab (UCB0107)

Multiple Sclerosis (MS)

NAD+ Precursors for Neurodegeneration

Pathway Diagram

Outgoing (415)

Incoming (247)

Targeting Hypotheses (30)

Mentioning Analyses (30)

Are age-related static epigenetic patterns pathogenic or protective compensatory

What molecular mechanisms link elevated sphingomyelin synthase activity to incre

Why does Metformin fail to delay CJD progression despite improving anti-aging ha

What specific molecular mechanisms link APOE4 to cholesterol dysregulation in ol

What is the molecular mechanism by which oligodendroglial MCT1 disruption causes

What mechanisms explain how IDH1/IDH2 mutations with reduced enzymatic activity

What is the therapeutic window between insufficient and toxic levels of TDP-43 a

How can Allen Aging Mouse Brain Atlas data be systematically cross-referenced wi

How can circuit-level neurodegeneration mechanisms be identified without complet

Is myelin loss in AD causal or an adaptive response to neuronal damage?

What is the optimal ketone dosing threshold to avoid metabolic steal syndrome wh

What is the optimal BBB opening duration and spatial precision to maximize thera

Which specific metabolic pathways in APOE4 microglia are causally linked to dysf

Does tau aggregation specifically cause PS externalization in vesicles independe

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

Can metabolic interventions truly reverse established cellular senescence or onl

What is the optimal therapeutic window timing for autophagy enhancement versus s

Do microglia actually switch between glycolytic and oxidative phosphorylation as

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

What is the therapeutic window between tau propagation inhibition and essential

Epigenetic reprogramming in aging neurons

Neuroinflammation and microglial priming in early AD

Neuroinflammation and microglial priming in early Alzheimer's Disease

Which metabolic biomarkers can distinguish therapeutic response from disease pro

How do astrocyte-neuron metabolic interactions change during disease progression

Which metabolic biomarkers can distinguish therapeutic response from disease pro

How do astrocyte-neuron metabolic interactions change during disease progression

Lipid metabolism dysregulation and membrane integrity in Alzheimer disease

Related Papers (20)